CIMIT Alliance with Singapore’s A*STAR to expand consortium engineering and technology implementation resources.
Boston - CIMIT and A*STAR have announced the formation of a strategic alliance between the two organizations, a relationship that will open new doors of opportunity for collaboration between CIMIT consortium researchers and clinician, engineering and technology colleagues in Singapore.
“Patients are the real beneficiaries of this alliance,” CIMIT executive director, John A. Parrish said in making the announcement in Boston. “Through this border-crossing multidisciplinary research and organizational collaboration, we have a unique opportunity to create and accelerate the adoption of novel technologies into clinical care.”
In forming this alliance with CIMIT, A*STAR seeks to enhance its long-term goal of building a vibrant MedTech innovation ecosystem in Singapore. For the CIMIT community, the collaboration adds important engineering and technology implementation capacity and expertise to the growing portfolio of resources available for Boston-based, clinically-focused innovators.
Details of the Collaboration
Under the Memorandum of Understanding, A*STAR and CIMIT will work together to:
A*Star and CIMIT will roll out these activities during 2010 and the relationship is expected to span several years.
CIMIT fosters and nurtures interdisciplinary collaboration among world-class experts in medicine, science and engineering, in concert with industry and government, to rapidly improve patient care. A non-profit consortium of Boston area teaching hospitals and engineering schools, CIMIT provides innovators with resources to explore, develop and implement novel technological solutions for today’s most urgent healthcare problems.
The Agency for Science, Technology and Research is the lead agency that drives biomedical and physical sciences and engineering research in Singapore. It oversees 23 research institutes, consortia and centers.
About the MedTech Industry in Singapore
The medical technology (MedTech) sector is part of Singapore’s burgeoning biomedical sciences industry. In 2008, the MedTech sector’s manufacturing output was about S$3 billion and employed more than 8,200 people.
Today, 25 global medical technology companies have invested in commercial-scale manufacturing plants in Singapore. They develop and manufacture a wide range of medical products, such as contact lenses, scientific analytical equipment, implantables, syringes, stents, catheters and hearing aids as well as research instruments. Today, Singapore is a global leader in medical technology manufacturing and accounts for 10% of the global supply of contact lens, half of the world’s thermal cyclers and more than 50% of the world’s microarray.